CHROMID® MDRO range for resistance management

Culture media range to fight Antimicrobial Resistance and HAI

Help fight Antimicrobial Resistance and Healthcare Associated Infections (HAI) with a range of chromogenic media designed specifically to provide reliable screening for relevant pathogens

  • Range designed specifically for today’s microbiology challenges
  • Sensitivity & specificity for reliable results
  • Easy to read thanks to color intensity & specificity
Add to your selection

Do you need more information?

The fight against drug resistance and Healthcare Associated Infections

Growing resistance of organisms to antimicrobial therapies is causing major patient-care and economic challenges for healthcare systems. Some organisms – referred to as multi-drug resistant organisms (MDRO) – are becoming resistant to multiple types or classes of antimicrobials. Resistant organisms are also frequently involved in the spread of Healthcare Associated Infections (HAI). The US Centers for Disease Control published in-depth reports on MDRO threat in 2013 and 2019. The good news is that between 2013 and 2019, efforts to use antibiotics more appropriately and implement infection control – practices that follow Antimicrobial Stewardship guidelines – reduced infection rates and death in the US. Yet, as the 2019 report states, “the emergence and spread of new forms of resistance continues to alarm CDC experts.1

For best patient care and to prevent the spread of disease, Antimicrobial Stewardship continues to be critical, including the implementation of appropriate antimicrobial therapy as soon as possible, based on rapid testing to identify the pathogens involved and test for their resistance.

Leveraging our expertise in high-quality chromogenic culture media, bioMérieux brings you the CHROMID® MDRO range to test for some of the “top-offenders” in drug resistance and HAI.

  • Standardized method: antibiotic concentration is controlled for each batch
  • Easy to read: many plates include chromogenic substrates and peptones to enable specific coloration for clear identification
  • Decrease the number of confirmation tests thanks to high performance
    • Time saving
    • Cost saving
    • Lower workload
  • A Certificate of Compatibility ensures compatibility with complementary products, including ID/AST

1. Antibiotic Resistance Threats in the United States, CDC 2013

CHROMID® Colistin R Agar

  • Screening of Enterobacterales colistin-resistant micro-organisms in clinical and veterinary samples.
  • Facilitates identification of colistin resistance carriers.
  • 88.1% sensitivity to report results with confidence.
  • Identification: 18/24 hours


  • Bi-plate offering smart association of CHROMID® CARBA and CHROMID® OXA-48
  • Screening of all carbapenemase producer Enterobacterales, including OXA-48, KPC and NDM-1 and more
  • Validated for both rectal swabs and stool specimens
  • Identification: 18/24 hours


  • Direct identification of MRSA
  • Improved recovery of mecC MRSA
  • Less additional work thanks to 99.6% specificity
  • Identification: 18/24 hours


  • Patented mix of antibiotics for selective growth of extended-Spectrum ß-Lactamase-producing Enterobacterales (ESBL) offers high sensitivity
  • Patented mix of 3 substrates to enable direct identification of the most frequent ESBL
  • Isolation and identification of E. coli, KESC*, Proteus ESBL producers
  • Identification: 18/24 hours

* Klebsiella, Enterobacter, Serratia and Citrobacter


  • Specific and selective isolation and detection of acquired Vancomycin-Resistant enterococci (VRE)
  • Differentiation of Vancomycin-Resistant E. faecium and E. faecalis
  • Detection of VanA and VanB genotypes
  • Selective mix inhibits enterococci with natural resistance (VanC), most Gram-negative and Gram-positive bacteria, and yeasts
  • Identification : 24 hours

CHROMID® C. difficile Agar

  • Chromogenic medium for the detection and identification of clostridioides difficile in stools of symptomatic patients
  • Rich nutritive base and patented chromogenic substrates to detect specific metabolic enzymes for C. difficile
  • Antibiotic mixture inhibits most Gram-negative and Gram-positive bacteria, yeasts and molds
  • Identification of C. difficile in 24 hours


  • Detection of two MDROs
  • Screening of extended-Spectrum ß-lactamase-producing Enterobacterales (ESBL)
  • Detection and differentiation of Enterococcus faecium and Enterococcus faecalis showing acquired Vancomycin resistance (VRE)
  • Identification: 18/24 hours


  • Screening of extended-Spectrum ß-lactamase-producing Enterobacterales (ESBL) and Gram-negative bacilli
  • Identification: 18/24 hours


CHROMID® MDRO range for SMART resistance management: technical specifications and reference numbers
CHROMID® Colistin R 421170 20 plates x 90 mm
CHROMID® CARBA SMART 414685 20 biplates x 90 mm

20 x 90 mm

100 x 90 mm
CHROMID ® ESBL 43481 20 x 90 mm
CHROMID® VRE 43004 20 x 90 mm
CHROMID® C.difficile 43871 20 x 90 mm
CHROMID® ESBL /  CHROMID® VRE 43470 20 biplates x 90 mm
CHROMID® BLSE agar AEB 5225770 20 x 90 mm


Please consult your local bioMérieux representative for product availability in your country

Pioneering diagnostics